This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (25)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Bullous Diseases  • Pemphigus  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Daniel Mimouni, MD; Grant J. Anhalt, MD; Deborah L. Cummins, BS; David J. Kouba, MD, PhD; Jennifer E. Thorne, MD; H. Carlos Nousari, MD

Arch Dermatol. 2003;139:739-742.

Background  Mycophenolate mofetil is increasingly being used as a corticosteroid-sparing agent in immunosuppressive regimens.

Objective  To elucidate the effectiveness of mycophenolate as adjuvant therapy in the treatment of both pemphigus vulgaris and pemphigus foliaceus.

Design  Historical prospective study.

Setting  University hospital.

Patients  The study included 42 consecutive patients with pemphigus (31 with pemphigus vulgaris and 11 with pemphigus foliaceus) who had relapses during prednisone taper or had clinically significant adverse effects from previous drug therapy.

Results  Remission was achieved in 22 (71%) and 5 (45%) of patients with pemphgus vulgaris and pemphigus foliaceus, respectively. Partial remission was achieved in 1 (3%) and 4 (36%), respectively. The median time to achieve complete remission was 9 months (range, 1-13 months). The treatment was administered for a median of 22 months, and the median follow-up period was 22 months. Seventy-seven percent of patients had no adverse effect. Two patients had side effects severe enough to necessitate discontinuation of treatment, one because of symptomatic but reversible neutropenia and the other because of nausea.

Conclusion  Mycophenolate is an effective and safe adjuvant in the treatment of both pemphigus vulgaris and pemphigus foliaceus.

From the Department of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, Md. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil
Martini et al.
Rheumatology (Oxford) 2009;48:1410-1413.
ABSTRACT | FULL TEXT  

Kinetics of Response to Conventional Treatment in Patients With Pemphigus Vulgaris
Czernik and Bystryn
Arch Dermatol 2008;144:682-683.
FULL TEXT  

Multicenter Randomized, Double-blind, Placebo-Controlled, Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris
Werth et al.
Arch Dermatol 2008;144:25-32.
ABSTRACT | FULL TEXT  

A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Pemphigus.
Beissert et al.
Arch Dermatol 2006;142:1447-1454.
ABSTRACT | FULL TEXT  

Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy
Heffernan et al.
JAMA 2006;295:1300-1303.
FULL TEXT  

Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT  

Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT  

Mycophenolate Mofetil for Pemphigus
Journal Watch Dermatology 2003;2003:1-1.
FULL TEXT